With fewer new drugs have marketing approval in the United States.

Trends. Is ready to take off after years of declining R & D productivity – Tufts Center for the Study Of Drug DevelopmentAfter years of declining R & D productivity, with fewer new drugs have marketing approval in the United States , drug developers willing to reverse the trend, according to the Tufts Center for the Study of Drug Development.

– More prescription-to-over – the-counter switches will take place in 2006 as a pressure growing on the FDA to allow them.About the Tufts Center for the Study of Drug Development The Tufts Center for the Study of Drug Development (at Tufts University provides strategic information to drug developers, regulators, and policy makers to improve the quality and efficiency of pharmaceutical development, review and use. Tufts CSDD, based in Boston, performs a wide range of in-depth analyzes on pharmaceutical issues and hosts symposia, workshops, and public forums on related topics, and publishes the Tufts CSDD Impact Report, a bimonthly newsletter analysis and insight into critical development drug questions.. – Biotech companies seek the development of therapeutic and vaccine products increasingly U.S.RetinoStat uses an LentiVector to deliver the retina onto the retina , which to block the formation of new blood vessels, AMD perform. Oxford BioMedica checks two versions RetinoStat with anti -angiogenic genes, endostatin was and angiostatin be.